Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Inventory (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Inventory for 9 consecutive years, with $608.2 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 22.88% to $608.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $608.2 million through Dec 2025, up 22.88% year-over-year, with the annual reading at $608.2 million for FY2025, 22.88% up from the prior year.
  • Inventory for Q4 2025 was $608.2 million at BeOne Medicines, up from $531.7 million in the prior quarter.
  • The five-year high for Inventory was $608.2 million in Q4 2025, with the low at $73.0 million in Q1 2021.
  • Average Inventory over 5 years is $348.6 million, with a median of $319.1 million recorded in 2023.
  • The sharpest move saw Inventory surged 324.99% in 2021, then grew 8.94% in 2023.
  • Over 5 years, Inventory stood at $242.6 million in 2021, then grew by 16.37% to $282.3 million in 2022, then surged by 47.38% to $416.1 million in 2023, then grew by 18.95% to $495.0 million in 2024, then grew by 22.88% to $608.2 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $608.2 million, $531.7 million, and $502.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.